
Prediction of idiopathic pulmonary fibrosis (IPF) progression is vital for the choice and timing of treatment and patient follow‐up. This could potentially be achieved by prognostic blood biomarkers of extracellular matrix (ECM) remodelling. Neoepitope biomarkers of types III and VI collagen turnover (C3M, C6M, PRO‐C3 and PRO‐C6) were measured in 185 patients with newly diagnosed IPF. Disease severity at baseline and progression over 6 months was assessed by lung function tests and 6‐min walk tests...
Like
Save
Share